Shenjing Li, MD
Interventional Cardiology · Vancouver, WANPI 1568892586
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,395 of the $4,474 with a category attached, or 75.9%. 7 manufacturers reported payments, led by Abbott at 40.3% of the total. Reporting peaked in 2020 at $1,738 and has fallen 96.4% since, to $63 in 2025. That places this record below the midpoint for interventional cardiology clinicians in WA, where the typical reported total is $3,955.
Across 43 payments — averaging $104.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Biotronik Inc.$1K
- Medtronic$1K
- Penumbra, Inc.$67
- Boston Scientific$49
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16
- plus $15 from 1 others
Across 1 payment — averaging $2125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$2K
What the payments were for
- Travel & lodging$3,39576%
- Food & beverage$1,07924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $1,801 |
| Biotronik Inc. | 16 | $1,322 |
| Medtronic | 11 | $1,204 |
| Penumbra, Inc. | 1 | $67 |
| Boston Scientific | 1 | $49 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Abiomed | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,544
- Micra$743
- Amplia MRI$144
How this compares
$4,474 in reported general payments places this provider in the 50th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 193 | $248,878 |
| EliquisApixaban | 181 | $246,803 |
| EntrestoSacubitril/Valsartan | 87 | $130,195 |
| XareltoRivaroxaban | 74 | $98,737 |
| Repatha SureclickEvolocumab | 74 | $68,444 |
| BrilintaTicagrelor | 17 | $15,698 |
| Praluent PenAlirocumab | 15 | $7,801 |
| Metoprolol Succinate | 425 | $6,597 |
| Rosuvastatin Calcium | 352 | $5,825 |
| Ezetimibe | 208 | $4,301 |
| Atorvastatin Calcium | 420 | $4,052 |
| Losartan Potassium | 249 | $2,557 |
| ClopidogrelClopidogrel Bisulfate | 172 | $2,108 |
| Carvedilol | 157 | $1,720 |
| Spironolactone | 197 | $1,459 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Vancouver
- Vishesh KumarVancouver$95K
- Nathan BoyerVancouver$13K
- Timothy SimpsonVancouver$13K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.